Andersen PH - Search Results

1

A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.

Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, Thogersen H, Hansen TK, Peschke B, Lau J, Lundt BF, Andersen PH. Ankersen M, et al. Among authors: andersen ph. J Med Chem. 1998 Sep 10;41(19):3699-704. doi: 10.1021/jm9801962. J Med Chem. 1998. PMID: 9733495

2

Novel orally active growth hormone secretagogues.

Hansen TK, Ankersen M, Hansen BS, Raun K, Nielsen KK, Lau J, Peschke B, Lundt BF, Thøgersen H, Johansen NL, Madsen K, Andersen PH. Hansen TK, et al. Among authors: andersen ph. J Med Chem. 1998 Sep 10;41(19):3705-14. doi: 10.1021/jm980197u. J Med Chem. 1998. PMID: 9733496

3

Ipamorelin, the first selective growth hormone secretagogue.

Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Raun K, et al. Among authors: andersen ph. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. Eur J Endocrinol. 1998. PMID: 9849822

4

Pharmacological characterisation of a new oral GH secretagogue, NN703.

Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M. Hansen BS, et al. Among authors: andersen ph. Eur J Endocrinol. 1999 Aug;141(2):180-9. doi: 10.1530/eje.0.1410180. Eur J Endocrinol. 1999. PMID: 10427162

5

The growth hormone-releasing hormone receptor: desensitisation following short-term agonist exposure.

Hansen BS, Gerlach LO, Hansen A, Foged C, Andersen PH. Hansen BS, et al. Among authors: andersen ph. Pharmacol Toxicol. 2001 Feb;88(2):81-8. doi: 10.1034/j.1600-0773.2001.d01-87.x. Pharmacol Toxicol. 2001. PMID: 11169166

6

NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists.

Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB. Andersen PH, et al. Eur J Pharmacol. 1992 Aug 14;219(1):45-52. doi: 10.1016/0014-2999(92)90578-r. Eur J Pharmacol. 1992. PMID: 1397049

7

Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy.

Andersen PH, Jansen JA. Andersen PH, et al. Eur J Pharmacol. 1990 Jun 12;188(6):335-47. doi: 10.1016/0922-4106(90)90194-3. Eur J Pharmacol. 1990. PMID: 1973652

8

Characteristics of stably expressed human dopamine D1a and D1b receptors: atypical behavior of the dopamine D1b receptor.

Pedersen UB, Norby B, Jensen AA, Schiødt M, Hansen A, Suhr-Jessen P, Scheideler M, Thastrup O, Andersen PH. Pedersen UB, et al. Among authors: andersen ph. Eur J Pharmacol. 1994 Mar 15;267(1):85-93. doi: 10.1016/0922-4106(94)90228-3. Eur J Pharmacol. 1994. PMID: 8206133

9

Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists.

Nielsen EB, Andersen PH. Nielsen EB, et al. Among authors: andersen ph. Eur J Pharmacol. 1992 Aug 14;219(1):35-44. doi: 10.1016/0014-2999(92)90577-q. Eur J Pharmacol. 1992. PMID: 1397048

10

Functional importance of the carboxyl tail cysteine residues in the human D1 dopamine receptor.

Jensen AA, Pedersen UB, Kiemer A, Din N, Andersen PH. Jensen AA, et al. Among authors: andersen ph. J Neurochem. 1995 Sep;65(3):1325-31. doi: 10.1046/j.1471-4159.1995.65031325.x. J Neurochem. 1995. PMID: 7643110

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

269 results

Search Page

Filters